Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice?

Research output: Contribution to journalArticle

Abstract

Aims and background. Few studies show what happens outside of randomized clinical trials. The purpose of the study was to describe the clinical management of metastatic gastric cancer patients resident in the Forlì area from 2000 to 2009. Methods and study design. A total of 270 metastatic gastric cancer patients at diagnosis or relapse were considered. Data from medical records were analysed, and survival probabilities were calculated using the Kaplan-Meier method. Results. A total of 115 patients received best supportive care, 155 at least one line of chemotherapy, 71 (45.8%) underwent second-line therapy, and 49 (31.6%) required a drug dose reduction during the first cycle of first-line therapy. Twelve (7.7%) patients died within 15 days of finishing the last chemotherapy. Median overall survival with best supportive care or chemotherapy was 3 months (95% CI, 2-4) and 11 months (95% CI, 9-12) (P

Original languageEnglish
Pages (from-to)583-588
Number of pages6
JournalTumori
Volume99
Issue number5
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Stomach Neoplasms
Drug Therapy
Survival
Medical Records
Randomized Controlled Trials
Recurrence
Therapeutics
Pharmaceutical Preparations

Keywords

  • Clinical practice
  • Dose reduction
  • End of life
  • Metastatic gastric cancer
  • Outcome research
  • Second-line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{dbf5297cd4d74248b5aaf7b7d4093620,
title = "Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice?",
abstract = "Aims and background. Few studies show what happens outside of randomized clinical trials. The purpose of the study was to describe the clinical management of metastatic gastric cancer patients resident in the Forl{\`i} area from 2000 to 2009. Methods and study design. A total of 270 metastatic gastric cancer patients at diagnosis or relapse were considered. Data from medical records were analysed, and survival probabilities were calculated using the Kaplan-Meier method. Results. A total of 115 patients received best supportive care, 155 at least one line of chemotherapy, 71 (45.8{\%}) underwent second-line therapy, and 49 (31.6{\%}) required a drug dose reduction during the first cycle of first-line therapy. Twelve (7.7{\%}) patients died within 15 days of finishing the last chemotherapy. Median overall survival with best supportive care or chemotherapy was 3 months (95{\%} CI, 2-4) and 11 months (95{\%} CI, 9-12) (P",
keywords = "Clinical practice, Dose reduction, End of life, Metastatic gastric cancer, Outcome research, Second-line",
author = "Manlio Monti and Flavia Foca and Gardini, {Andrea Casadei} and Martina Valgiusti and Frassineti, {Giovanni Luca} and Dino Amadori",
year = "2013",
month = "9",
doi = "10.1700/1377.15306",
language = "English",
volume = "99",
pages = "583--588",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice?

AU - Monti, Manlio

AU - Foca, Flavia

AU - Gardini, Andrea Casadei

AU - Valgiusti, Martina

AU - Frassineti, Giovanni Luca

AU - Amadori, Dino

PY - 2013/9

Y1 - 2013/9

N2 - Aims and background. Few studies show what happens outside of randomized clinical trials. The purpose of the study was to describe the clinical management of metastatic gastric cancer patients resident in the Forlì area from 2000 to 2009. Methods and study design. A total of 270 metastatic gastric cancer patients at diagnosis or relapse were considered. Data from medical records were analysed, and survival probabilities were calculated using the Kaplan-Meier method. Results. A total of 115 patients received best supportive care, 155 at least one line of chemotherapy, 71 (45.8%) underwent second-line therapy, and 49 (31.6%) required a drug dose reduction during the first cycle of first-line therapy. Twelve (7.7%) patients died within 15 days of finishing the last chemotherapy. Median overall survival with best supportive care or chemotherapy was 3 months (95% CI, 2-4) and 11 months (95% CI, 9-12) (P

AB - Aims and background. Few studies show what happens outside of randomized clinical trials. The purpose of the study was to describe the clinical management of metastatic gastric cancer patients resident in the Forlì area from 2000 to 2009. Methods and study design. A total of 270 metastatic gastric cancer patients at diagnosis or relapse were considered. Data from medical records were analysed, and survival probabilities were calculated using the Kaplan-Meier method. Results. A total of 115 patients received best supportive care, 155 at least one line of chemotherapy, 71 (45.8%) underwent second-line therapy, and 49 (31.6%) required a drug dose reduction during the first cycle of first-line therapy. Twelve (7.7%) patients died within 15 days of finishing the last chemotherapy. Median overall survival with best supportive care or chemotherapy was 3 months (95% CI, 2-4) and 11 months (95% CI, 9-12) (P

KW - Clinical practice

KW - Dose reduction

KW - End of life

KW - Metastatic gastric cancer

KW - Outcome research

KW - Second-line

UR - http://www.scopus.com/inward/record.url?scp=84893492993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893492993&partnerID=8YFLogxK

U2 - 10.1700/1377.15306

DO - 10.1700/1377.15306

M3 - Article

AN - SCOPUS:84893492993

VL - 99

SP - 583

EP - 588

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -